Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Bacopa Monnieri | Fasoracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands) | 20-100 mg 1-3 times daily (sublingual or oral) |
| Timing | With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects. | Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food. |
| Cycle Duration | Ongoing; benefits accumulate over months. No strict cycling required. | Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data. |
| Evidence Level | strong_human | animal_plus_anecdotal |
Active triterpenoid saponins (bacosides A and B) provide multifaceted neuroprotection: inhibition of acetylcholinesterase (AChE) and activation of choline acetyltransferase (ChAT) to enhance cholinergic neurotransmission; upregulation of tryptophan hydroxylase and serotonin transporter expression to modulate serotonergic tone; antioxidant neuroprotection via induction of superoxide dismutase and glutathione peroxidase; and reduction of beta-amyloid aggregation. Additionally enhances GABA signaling through GABA-A receptor subunit upregulation and glutamate decarboxylase activation.
300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands)
With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects.
Ongoing; benefits accumulate over months. No strict cycling required.
Non-classical racetam that modulates all three groups of metabotropic glutamate receptors (mGluR Groups I, II, and III) and upregulates GABA-B receptors — a unique mechanism that distinguishes it from other racetams. Also enhances high-affinity choline uptake (HACU) and stimulates acetylcholine release. Does not significantly affect adrenergic, serotonergic, or dopaminergic receptors. The GABA-B upregulation is particularly notable as it may counteract GABA-B receptor downregulation caused by phenibut or baclofen tolerance.
20-100 mg 1-3 times daily (sublingual or oral)
Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →